CDC42BPB.md
... ...
@@ -1,4 +1,4 @@
1
-# CCDC42BPB
1
+# CDC42BPB
2 2
3 3
## History
4 4
Mutations in this gene were first described in FL in 2021 by Hübschmann et al.<sup>1</sup>
... ...
@@ -22,21 +22,7 @@ timeline
22 22
|:------:|:-------------:|:-------------:|
23 23
|FL |GAMBL genomes|NA |
24 24
25
-## Mutation pattern and selective pressure estimates
26 25
27
-|
28
-
29
-
30
-
31
-
32
-View coding variants in ProteinPaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/CCDC42BPB_protein.html) or [hg38](https://morinlab.github.io/LLMPP/GAMBL/CCDC42BPB_protein_hg38.html)
33
-
34
-View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/CCDC42BPB.html) or [hg38](https://morinlab.github.io/LLMPP/GAMBL/CCDC42BPB_hg38.html)
35
-
36
-![](images/proteinpaint/CCDC42BPB.svg)
37
-
38
-## CCDC42BPB Expression
39
-![](images/gene_expression/CCDC42BPB_by_pathology.svg)
40 26
41 27
## References
42 28
1. Hübschmann D, Kleinheinz K, Wagener R, Bernhart SH, López C, Toprak UH, Sungalee S, Ishaque N, Kretzmer H, Kreuz M, Waszak SM, Paramasivam N, Ammerpohl O, Aukema SM, Beekman R, Bergmann AK, Bieg M, Binder H, Borkhardt A, Borst C, Brors B, Bruns P, Carrillo de Santa Pau E, Claviez A, Doose G, Haake A, Karsch D, Haas S, Hansmann ML, Hoell JI, Hovestadt V, Huang B, Hummel M, Jäger-Schmidt C, Kerssemakers JNA, Korbel JO, Kube D, Lawerenz C, Lenze D, Martens JHA, Ott G, Radlwimmer B, Reisinger E, Richter J, Rico D, Rosenstiel P, Rosenwald A, Schillhabel M, Stilgenbauer S, Stadler PF, Martín-Subero JI, Szczepanowski M, Warsow G, Weniger MA, Zapatka M, Valencia A, Stunnenberg HG, Lichter P, Möller P, Loeffler M, Eils R, Klapper W, Hoffmann S, Trümper L, ICGC MMML-Seq consortium, ICGC DE-Mining consortium, BLUEPRINT consortium, Küppers R, Schlesner M, Siebert R. Mutational mechanisms shaping the coding and noncoding genome of germinal center derived B-cell lymphomas. Leukemia. 2021 Jul;35(7):2002–2016. PMCID: PMC8257491
papers/hubschmannMutationalMechanismsShaping2021b.md
... ...
@@ -44,11 +44,11 @@ All other DLBCL studies, DLBCL Tier 2, 175
44 44
### Tier 2
45 45
|New gene|FL tier|DLBCL tier|Average variant quality|QC outcome|
46 46
|:-|:-:|:-:|:-:|:-:|
47
-|[ADAMTS1](../ADAMTS1)| |2 |&starf; &starf; &starf; &star; &star; | *Pass* |
48
-|[ANKRD12](../ANKRD12)| |2 |&starf; &starf; &starf; &star; &star; | *Pass* |
49
-|[ATP6V1A](../ATP6V1A)|2 | |&starf; &starf; &starf; &starf; &star; | *Pass* |
50
-|[CADPS2](../CADPS2)| |2 |&starf; &starf; &starf; &starf; &star; | *Pass* |
51
-|[CDC42BPB](../CDC42BPB)|2 | |||
47
+|[ADAMTS1](../ADAMTS1)| |2 |&starf; &starf; &starf; &star; &star; | **Pass** |
48
+|[ANKRD12](../ANKRD12)| |2 |&starf; &starf; &starf; &star; &star; | **Pass** |
49
+|[ATP6V1A](../ATP6V1A)|2 | |&starf; &starf; &starf; &starf; &star; | **Pass** |
50
+|[CADPS2](../CADPS2)| |2 |&starf; &starf; &starf; &starf; &star; | **Pass** |
51
+|[CDC42BPB](../CDC42BPB)|2 | *None* | *None* | **Fail** |
52 52
|[CNOT2](../CNOT2)| |2 |||
53 53
|[CPNE8](../CPNE8)|2 | |||
54 54
|[DHX15](../DHX15)|2 | |||